Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dibotermin alfa + calcium phosphate matrix is a combination therapeutic consisting of **recombinant human bone morphogenetic protein-2 (rhBMP-2)** formulated with a **calcium phosphate matrix** for surgical implantation. **Dibotermin alfa** is a protein produced using recombinant DNA technology in CHO (Chinese Hamster Ovary) cells and is a potent osteoinductive agent—meaning it induces the formation of new bone by stimulating the differentiation of mesenchymal cells into osteoblasts and chondrocytes. The **calcium phosphate matrix** serves as an osteoconductive scaffold, supporting bone cell attachment and growth. This combination is indicated as an adjunct for spinal fusion and to promote healing in acute tibial fractures by supporting robust bone regeneration at the site of implantation. The mechanisms involve activation of type I and II bone morphogenetic protein (BMP) receptors on mesenchymal cells, propagating signals through the Smad pathway to induce new bone and cartilage formation. The combination leverages both the cellular signaling (rhBMP-2) and physical/structural support (calcium phosphate matrix) to enhance bone healing and repair[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dibotermin alfa + calcium phosphate matrix.